Geoffrey Alexander Smith, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Interleukin-2 Receptor beta Subunit | 1 | 2017 | 25 | 0.600 |
Why?
|
| Interleukin-2 | 3 | 2017 | 1891 | 0.530 |
Why?
|
| Janus Kinase 3 | 1 | 2016 | 76 | 0.520 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2016 | 562 | 0.470 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2017 | 4370 | 0.360 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2017 | 4575 | 0.280 |
Why?
|
| STAT Transcription Factors | 2 | 2018 | 188 | 0.170 |
Why?
|
| Janus Kinases | 2 | 2018 | 248 | 0.170 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2017 | 86 | 0.150 |
Why?
|
| Signal Transduction | 4 | 2018 | 23441 | 0.150 |
Why?
|
| Education, Distance | 1 | 2021 | 260 | 0.140 |
Why?
|
| STAT5 Transcription Factor | 1 | 2017 | 264 | 0.140 |
Why?
|
| Interleukin-7 | 1 | 2017 | 142 | 0.140 |
Why?
|
| Receptor Cross-Talk | 1 | 2017 | 116 | 0.140 |
Why?
|
| S Phase | 1 | 2017 | 421 | 0.140 |
Why?
|
| Peptide Elongation Factor 1 | 1 | 2015 | 39 | 0.130 |
Why?
|
| Drug Repositioning | 1 | 2018 | 233 | 0.130 |
Why?
|
| Receptors, IgE | 1 | 2016 | 374 | 0.120 |
Why?
|
| Peptides, Cyclic | 1 | 2015 | 392 | 0.110 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 382 | 0.110 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2016 | 1693 | 0.100 |
Why?
|
| Immunity, Cellular | 1 | 2017 | 1560 | 0.100 |
Why?
|
| Pyrroles | 1 | 2018 | 1125 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 4 | 2017 | 22163 | 0.100 |
Why?
|
| Immunoglobulin E | 1 | 2016 | 1495 | 0.090 |
Why?
|
| Cell Death | 1 | 2015 | 1677 | 0.090 |
Why?
|
| Autoimmunity | 1 | 2017 | 1355 | 0.080 |
Why?
|
| Piperidines | 1 | 2018 | 1656 | 0.080 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 6532 | 0.070 |
Why?
|
| Bone Marrow | 1 | 2018 | 2910 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2017 | 2549 | 0.070 |
Why?
|
| Glucocorticoids | 1 | 2017 | 2161 | 0.070 |
Why?
|
| Interferon-gamma | 1 | 2016 | 3159 | 0.070 |
Why?
|
| Cell Proliferation | 3 | 2017 | 10441 | 0.070 |
Why?
|
| Phosphorylation | 1 | 2017 | 8320 | 0.070 |
Why?
|
| Cells, Cultured | 3 | 2017 | 18964 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 4014 | 0.070 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 5490 | 0.060 |
Why?
|
| Pyrimidines | 1 | 2018 | 3027 | 0.060 |
Why?
|
| Tumor Microenvironment | 1 | 2018 | 3874 | 0.060 |
Why?
|
| Mice | 5 | 2018 | 81509 | 0.060 |
Why?
|
| Antineoplastic Agents | 2 | 2017 | 13637 | 0.050 |
Why?
|
| B-Lymphocytes | 1 | 2016 | 4764 | 0.050 |
Why?
|
| Apoptosis | 2 | 2016 | 9488 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 5305 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 5665 | 0.050 |
Why?
|
| Animals | 6 | 2018 | 168441 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2021 | 5879 | 0.040 |
Why?
|
| Multiple Myeloma | 1 | 2018 | 5146 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 3602 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 11902 | 0.040 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2017 | 67 | 0.030 |
Why?
|
| Mice, Inbred C3H | 1 | 2017 | 915 | 0.030 |
Why?
|
| Guanosine Triphosphate | 1 | 2015 | 316 | 0.030 |
Why?
|
| Models, Immunological | 1 | 2017 | 513 | 0.030 |
Why?
|
| Plasma Cells | 1 | 2018 | 599 | 0.030 |
Why?
|
| Mutant Proteins | 1 | 2015 | 491 | 0.030 |
Why?
|
| RNA, Transfer | 1 | 2015 | 292 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2017 | 548 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2021 | 1126 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2017 | 2065 | 0.020 |
Why?
|
| Cell Communication | 1 | 2018 | 1657 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2017 | 1405 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2017 | 16979 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2015 | 1595 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2017 | 1947 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2018 | 2448 | 0.020 |
Why?
|
| Male | 2 | 2017 | 360736 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 2021 | 2374 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 18247 | 0.020 |
Why?
|
| Proteome | 1 | 2018 | 1862 | 0.020 |
Why?
|
| Female | 2 | 2017 | 392581 | 0.020 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2018 | 1642 | 0.020 |
Why?
|
| Pediatrics | 1 | 2021 | 3595 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2017 | 2449 | 0.020 |
Why?
|
| Proteomics | 1 | 2018 | 3845 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 9535 | 0.010 |
Why?
|
| Protein Binding | 1 | 2015 | 9352 | 0.010 |
Why?
|
| Humans | 4 | 2021 | 761423 | 0.010 |
Why?
|
| Child | 1 | 2021 | 80162 | 0.010 |
Why?
|
| Mutation | 1 | 2015 | 30045 | 0.010 |
Why?
|